Synopsis: Coherence Lifesciences plunged 11% after Dr. V. Prasada Raju, the Managing Director, resigned from the board with immediate effect, stating personal reasons. However, the company mentioned that he will still be available to help during the transition period.
The shares of this leading pharmaceutical company are in focus after its key managerial personnel resigned from the board. In this article, we will dive into the details of this fall.
With a market capitalization of Rs 30,303 crore, the shares of Cohance Lifesciences Ltd reached a day’s low of Rs 766.80 per share, down 11 percent from its previous day’s closing price of Rs 859.70 per share. Over the past five years, the stock has delivered a return of 148 percent, outperforming NIFTY 50’s return of 123 percent.
Reason Behind this Fall
Cohance Lifesciences Limited announced that Dr. V. Prasada Raju has resigned from the post of Managing Director and Director of the company with immediate effect from October 28, 2025. Administration informed that he will cease to be a director as well as a key managerial personnel, but will be available to assist the company in the transition process.
Dr. Raju mentioned that his main reason for leaving the post of personal priorities and pursuing his learning journey. He thanked the Board, the employees, and the partners for their support and said that he was excited about the opportunity to contribute to the growth of Cohance as a successful, global company with a promising future.
Financial Highlights
The company reported revenue of Rs 549 crore in Q1 FY26, representing a 13 percent growth compared to Rs 488 crore in Q1 FY25. Regarding its profitability, the company reported a 39 percent decline in net profit to Rs 46 crore in Q1 FY26, compared to Rs 75 crore in Q1 FY25.
The stock delivered a poor ROE and ROCE of 12.67 percent and 14.89 percent respectively, and is currently trading at a high P/E of 86x as compared to its industry P/E of 32x.
Cohance Lifesciences Limited is a firm that builds and makes pharmaceutical ingredients, specialty chemicals, and formulated drugs for clients in India and foreign countries like the US and Europe. It offers a complete service package of R&D and contract manufacturing to global pharma and biotech companies.
The company produces a large variety of products that include small molecule APIs, drug intermediates, antibody drug conjugates, and ultrahigh-purity materials for next-generation medicines and chemicals. The company changed its name from Suven Pharmaceuticals Limited to Cohance Lifesciences Limited in May 2025.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
